MetaCap

Coherus Oncology (CHRS) vs Cardiff Oncology (CRDF)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cardiff Oncology (CRDF) has outperformed Coherus Oncology (CHRS) over the past year, losing 58.0% versus a loss of 68.1%. Over five years, CRDF leads with a -84.8% price change compared with -98.0% for CHRS. Cardiff Oncology is the larger company by market cap ($66.3 million vs $57.1 million), about 1.2 times the size, while Coherus Oncology is growing revenue faster (+59.8% vs -13.2%).

Coherus Oncology converts more of its revenue into profit, with a net margin of 398.4% versus -7732.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CHRS-68.12%CRDF-57.99%
+126%+24%-77%
Nov 21, 20251 yearNov 20, 2026
CHRS-98.00%CRDF-84.99%
+27%-39%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CHRS versus CRDF key metrics
MetricCHRSCRDF
Share price$0.3698$0.8528
Market cap$57.15M$66.34M
1-day change-4.47%-4.46%
YTD return-73.96%-69.65%
1-year return-68.12%-57.99%
5-year return-97.99%-84.80%
EPS (TTM)$-1.12$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$42.17M$593.00K
Revenue growth (YoY)+59.81%-13.18%
Net income (latest FY)$168.02M$-45.85M
Gross margin67.24%—
Operating margin-429.51%-8256.32%
Net margin398.43%-7732.04%
52-week high$2.62$3.31
52-week low$0.3628$0.71
Distance from 52-week high-85.86%-74.24%
Analyst consensusstrong_buynone
Avg. price target upside+1995.73%+581.29%
Average volume1.80M1.01M
Shares outstanding154.54M77.80M
Employees14430
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRDF has outperformed CHRS by 10.1 percentage points over the past year.
  • Coherus Oncology is more profitable, keeping 398.4 cents of every revenue dollar as net income versus -7732.0 cents for Cardiff Oncology.
  • Coherus Oncology grew revenue faster in its latest fiscal year (+59.81% vs -13.18%).

About Coherus Oncology

CHRS stock →

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

About Cardiff Oncology

CRDF stock →

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees

CHRS vs CRDF FAQ

Which is bigger, Coherus Oncology or Cardiff Oncology?

Cardiff Oncology (CRDF) is larger, with a market capitalization of $66.34M compared with $57.15M for Coherus Oncology (CHRS).

Which stock has performed better over the past year, CHRS or CRDF?

CRDF returned -57.99% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.

Are Coherus Oncology and Cardiff Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons